Crossmark

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)

Crossref DOI link: https://doi.org/10.1038/s41598-024-79272-8

Published Online: 2024-12-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Ning

Wang, Haijun

Chen, Ying

Wang, Yanfeng
Funding

Funding for this research was provided by:

CAMS Innovation Fund for Medical Sciences (2022-I2M-C&T-B-069)

Beijing Hope Run Special Fund of Cancer Foundation of China (LC2020A17)
License Information

Text and Data Mining valid from 2024-12-30

Version of Record valid from 2024-12-30
More Information

Article History

Received: 12 March 2024

Accepted: 7 November 2024

First Online: 30 December 2024

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below